Clinical experience with antiangiogenic therapy in leukemia

Current Cancer Drug Targets

Volumn 11, Issue 9, 2011, Pages 1053-1068

  Wellbrock, J ^a   Fiedler, W ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; Antiangiogenic therapy; Combined treatment; Imids; Leukemia; Mtor inhibitors; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

AZACITIDINE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; IDARUBICIN; LENALIDOMIDE; LESTAURTINIB; MIDOSTAURIN; MITOXANTRONE; RAPAMYCIN; RITUXIMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LEUKEMIA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PROLYMPHOCYTIC LEUKEMIA; REVIEW; T CELL LEUKEMIA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; LEUKEMIA; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; PYRROLES; QUINAZOLINES; STAUROSPORINE; THALIDOMIDE; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81155154413     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911798073078     Document Type: Review

References (119)

1. Cohen, M. H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007, 12, 356-361.
2. Rock, E. P.; Goodman, V.; Jiang, J. X.; Mahjoob, K.; Verbois, S. L.; Morse, D.; Dagher, R.; Justice, R.; Pazdur, R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007, 12, 107-113.
3. Sachdev, J. C.; Jahanzeb, M. Evolution of bevacizumab-based therapy in the management of breast cancer. Clin. Breast Cancer 2008, 8, 402-410.
4. Li, W. W.; Hutnik, M.; Gehr, G. Antiangiogenesis in haematological malignancies. Br. J. Haematol. 2008, 143, 622-631.
5. Schaefer, C.; Krause, M.; Fuhrhop, I.; Schroeder, M.; Algenstaedt, P.; Fiedler, W.; Ruther, W.; Hansen-Algenstaedt, N. Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo. Leukemia 2008, 22, 59-65.
6. Bieker, R.; Padro, T.; Kramer, J.; Steins, M.; Kessler, T.; Retzlaff, S.; Herrera, F.; Kienast, J.; Berdel, W. E.; Mesters, R. M. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res. 2003, 63, 7241-7246.
7. Fiedler, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D. K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997, 89, 1870-1875.
8. Fielder, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D. K. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997, 11, 1234-1237.
9. Loges, S.; Heil, G.; Bruweleit, M.; Schoder, V.; Butzal, M.; Fischer, U.; Gehling, U. M.; Schuch, G.; Hossfeld, D. K.; Fiedler, W. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J. Clin. Oncol. 2005, 23, 1109-1117.
10. de Jonge, H. J.; Valk, P. J.; Veeger, N. J.; ter Elst, A.; den Boer, M. L.; Cloos, J.; de Haas, V.; van den Heuvel-Eibrink, M. M.; Kaspers, G. J.; Zwaan, C. M.; Kamps, W. A.; Lowenberg, B.; de Bont, E. S. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010, 116, 1747-1754.
11. Nowicki, M.; Ostalska-Nowicka, D.; Kaczmarek, E.; Miskowiak, B.; Witt, M. Vascular endothelial growth factor C--a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach. Histopathology 2006, 49, 170-177.
12. Fiedler, W.; Schuch, G.; Loges, S. Prognostic implication of expression of Angiopoietin-2 in acute myeloid leukemia. Leuk. Res. 2008, 32, 843-844.
13. Hou, H. A.; Chou, W. C.; Lin, L. I.; Tang, J. L.; Tseng, M. H.; Huang, C. F.; Yao, M.; Chen, C. Y.; Tsay, W.; Tien, H. F. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk. Res. 2008, 32, 904-912.
14. Kharfan-Dabaja, M. A.; Patel, S. A.; Osunkoya, A. O.; Kojouri, K.; Kamble, R.; Yang, J.; Hashmi, M.; Ozer, H.; Selby, G. B. Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining. Clin. Lab Haematol. 2006, 28, 254-258.
15. Otten, J.; Schmitz, L.; Vettorazzi, E.; Schultze, A.; Marx, A. H.; Simon, R.; Krauter, J.; Loges, S.; Sauter, G.; Bokemeyer, C.; Fiedler, W. Expression of TGF-beta receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia. Leukemia 2011, 25, 375-379.
16. Oster, W.; Mertelsmann, R.; Herrmann, F. Role of colony-stimulating factors in the biology of acute myelogenous leukemia. Int. J. Cell Cloning 1989, 7, 13-29.
17. Perez-Atayde, A. R.; Sallan, S. E.; Tedrow, U.; Connors, S.; Allred, E.; Folkman, J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 1997, 150, 815-821.
18. Veiga, J. P.; Costa, L. F.; Sallan, S. E.; Nadler, L. M.; Cardoso, A. A. Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp. Hematol. 2006, 34, 610-621.
19. Aguayo, A.; Kantarjian, H.; Manshouri, T.; Gidel, C.; Estey, E.; Thomas, D.; Koller, C.; Estrov, Z.; O'Brien, S.; Keating, M.; Freireich, E.; Albitar, M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96, 2240-2245.
20. Dilly, S. A.; Jagger, C. J. Bone marrow stromal cell changes in haematological malignancies. J. Clin. Pathol. 1990, 43, 942-946.
21. Korkolopoulou, P.; Viniou, N.; Kavantzas, N.; Patsouris, E.; Thymara, I.; Pavlopoulos, P. M.; Terpos, E.; Stamatopoulos, K.; Plata, E.; Anargyrou, K.; Androulaki, A.; Davaris, P.; Yataganas, X. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 2003, 17, 89-97.
22. Lundberg, L. G.; Lerner, R.; Sundelin, P.; Rogers, R.; Folkman, J.; Palmblad, J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol. 2000, 157, 15-19.
23. Janowska-Wieczorek, A.; Majka, M.; Marquez-Curtis, L.; Wertheim, J. A.; Turner, A. R.; Ratajczak, M. Z. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002, 16, 1160-1166.
24. Mayerhofer, M.; Valent, P.; Sperr, W. R.; Griffin, J. D.; Sillaber, C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002, 100, 3767-3775.
25. Giles, F. J.; Kantarjian, H. M.; Bekele, B. N.; Cortes, J. E.; Faderl, S.; Thomas, D. A.; Manshouri, T.; Rogers, A.; Keating, M. J.; Talpaz, M.; O'Brien, S.; Albitar, M. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br. J. Haematol. 2002, 119, 38-45.
26. Verstovsek, S.; Kantarjian, H.; Manshouri, T.; Cortes, J.; Giles, F. J.; Rogers, A.; Albitar, M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002, 99, 2265-2267.
27. Verstovsek, S.; Kantarjian, H.; Manshouri, T.; O'Brien, S.; Faderl, S.; Talpaz, M.; Cortes, J.; Albitar, M. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer 2002, 94, 1517-1521.
28. Kini, A. R.; Kay, N. E.; Peterson, L. C. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000, 14, 1414-1418.
29. Molica, S.; Vitelli, G.; Levato, D.; Ricciotti, A.; Digiesi, G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br. J. Cancer 2002, 86, 31-35.
30. Peterson, L.; Kini, A. R. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 2001, 97, 2529.
31. Chen, H.; Treweeke, A. T.; West, D. C.; Till, K. J.; Cawley, J. C.; Zuzel, M.; Toh, C. H. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000, 96, 3181-3187.
32. Cortelezzi, A.; Fracchiolla, N. S.; Mazzeo, L. M.; Silvestris, I.; Pomati, M.; Somalvico, F.; Bertolini, F.; Mancuso, P.; Pruneri, G. C.; Gianelli, U.; Pasquini, M. C.; Cortiana, M.; Deliliers, G. L. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk. Lymphoma 2005, 46, 1345-1351.
33. Rigolin, G. M.; Maffei, R.; Rizzotto, L.; Ciccone, M.; Sofritti, O.; Daghia, G.; Cibien, F.; Cavazzini, F.; Marasca, R.; Cuneo, A. Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance. Cancer 2010, 116, 1926-1937.
34. Rigolin, G. M.; Mauro, E.; Ciccone, M.; Fraulini, C.; Sofritti, O.; Castoldi, G.; Cuneo, A. Neoplastic circulating endothelial-like cells in patients with acute myeloid leukaemia. Eur. J. Haematol. 2007, 78, 365-373.
35. Della Porta, M. G.; Malcovati, L.; Rigolin, G. M.; Rosti, V.; Bonetti, E.; Travaglino, E.; Boveri, E.; Galli, A.; Boggi, S.; Ciccone, M.; Pramparo, T.; Mazzini, G.; Invernizzi, R.; Lazzarino, M.; Cazzola, M. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia 2008, 22, 530-537.
36. Gora-Tybor, J.; Jamroziak, K.; Szmigielska-Kaplon, A.; Krawczynska, A.; Lech-Maranda, E.; Wierzbowska, A.; Jesionek-Kupnicka, D.; Blonski, J. Z.; Robak, T. Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 2009, 50, 62-67.
37. Otten, J.; Schultze, A.; Schafhausen, P.; Otterstetter, S.; Dierlamm, J.; Bokemeyer, C.; Brummendorf, T. H.; Fiedler, W.; Loges, S. Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative. Br. J. Haematol. 2008, 142, 115-118.
38. Piaggio, G.; Rosti, V.; Corselli, M.; Bertolotti, F.; Bergamaschi, G.; Pozzi, S.; Imperiale, D.; Chiavarina, B.; Bonetti, E.; Novara, F.; Sessarego, M.; Villani, L.; Garuti, A.; Massa, M.; Ghio, R.; Campanelli, R.; Bacigalupo, A.; Pecci, A.; Viarengo, G.; Zuffardi, O.; Frassoni, F.; Barosi, G. Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood 2009, 114, 3127-3130.
39. Shanafelt, T.; Zent, C.; Byrd, J.; Erlichman, C.; Laplant, B.; Ghosh, A.; Call, T.; Villalona-Calero, M.; Jelinek, D.; Bowen, D.; Laumann, K.; Wu, W.; Hanson, C.; Kay, N. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk. Lymphoma 2010, 51, 2222-2229.
40. Zahiragic, L.; Schliemann, C.; Bieker, R.; Thoennissen, N. H.; Burow, K.; Kramer, C.; Zuhlsdorf, M.; Berdel, W. E.; Mesters, R. M. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007, 21, 1310-1312.
41. Karp, J. E.; Gojo, I.; Pili, R.; Gocke, C. D.; Greer, J.; Guo, C.; Qian, D.; Morris, L.; Tidwell, M.; Chen, H.; Zwiebel, J. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 2004, 10, 3577-3585.
42. Fiedler, W.; Mesters, R.; Heuser, M.; Ehninger, G.; Berdel, W. E.; Zirrgiebel, U.; Robertson, J. D.; Puchalski, T. A.; Collins, B.; Jurgensmeier, J. M.; Serve, H. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk. Res. 2010, 34, 196-202.
43. Kiyoi, H.; Naoe, T. FLT3 in human hematologic malignancies. Leuk. Lymphoma 2002, 43, 1541-1547.
44. Fiedler, W.; Mesters, R.; Tinnefeld, H.; Loges, S.; Staib, P.; Duhrsen, U.; Flasshove, M.; Ottmann, O. G.; Jung, W.; Cavalli, F.; Kuse, R.; Thomalla, J.; Serve, H.; O'Farrell, A. M.; Jacobs, M.; Brega, N. M.; Scigalla, P.; Hossfeld, D. K.; Berdel, W. E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102, 2763-2767.
45. Loges, S.; Tinnefeld, H.; Metzner, A.; Jucker, M.; Butzal, M.; Bruweleit, M.; Fischer, U.; Draab, E.; Schuch, G.; O'-Farrel, A. M.; Hossfeld, D. K.; Bokemeyer, C.; Fiedler, W. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leuk. Lymphoma 2006, 47, 2601-2609.
46. Giles, F. J.; Stopeck, A. T.; Silverman, L. R.; Lancet, J. E.; Cooper, M. A.; Hannah, A. L.; Cherrington, J. M.; O'Farrell, A. M.; Yuen, H. A.; Louie, S. G.; Hong, W.; Cortes, J. E.; Verstovsek, S.; Albitar, M.; O'Brien, S. M.; Kantarjian, H. M.; Karp, J. E. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003, 102, 795-801.
47. Giles, F. J.; Cooper, M. A.; Silverman, L.; Karp, J. E.; Lancet, J. E.; Zangari, M.; Shami, P. J.; Khan, K. D.; Hannah, A. L.; Cherrington, J. M.; Thomas, D. A.; Garcia-Manero, G.; Albitar, M.; Kantarjian, H. M.; Stopeck, A. T. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer 2003, 97, 1920-1928.
48. O'Farrell, A. M.; Foran, J. M.; Fiedler, W.; Serve, H.; Paquette, R. L.; Cooper, M. A.; Yuen, H. A.; Louie, S. G.; Kim, H.; Nicholas, S.; Heinrich, M. C.; Berdel, W. E.; Bello, C.; Jacobs, M.; Scigalla, P.; Manning, W. C.; Kelsey, S.; Cherrington, J. M. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 2003, 9, 5465-5476.
49. Fiedler, W.; Serve, H.; Dohner, H.; Schwittay, M.; Ottmann, O. G.; O'Farrell, A. M.; Bello, C. L.; Allred, R.; Manning, W. C.; Cherrington, J. M.; Louie, S. G.; Hong, W.; Brega, N. M.; Massimini, G.; Scigalla, P.; Berdel, W. E.; Hossfeld, D. K. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105, 986-993.
50. Apostolidou, E.; Kantarjian, H.; Thomas, D.; Burger, I.; Borthakur, G.; Verstovsek, S. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clin. Lymphoma Myeloma Leuk. 2010, 10, 281-284.
51. Kancha, R. K.; Grundler, R.; Peschel, C.; Duyster, J. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp. Hematol. 2007, 35, 1522-1526.
52. Zhang, W.; Konopleva, M.; Shi, Y. X.; McQueen, T.; Harris, D.; Ling, X.; Estrov, Z.; Quintas-Cardama, A.; Small, D.; Cortes, J.; Andreeff, M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J. Natl. Cancer Inst. 2008, 100, 184-198.
53. Pratz, K. W.; Cho, E.; Levis, M. J.; Karp, J. E.; Gore, S. D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S. D.; Carducci, M. A.; Wright, J. J.; Rudek, M. A.; Smith, B. D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010, 24, 1437-1444.
54. Borthakur, G.; Kantarjian, H.; Ravandi, F.; Zhang, W.; Konopleva, M.; Wright, J. J.; Faderl, S.; Verstovsek, S.; Mathews, S.; Andreeff, M.; Cortes, J. E. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011, 96, 62-68.
55. Ravandi, F.; Cortes, J. E.; Jones, D.; Faderl, S.; Garcia-Manero, G.; Konopleva, M. Y.; O'Brien, S.; Estrov, Z.; Borthakur, G.; Thomas, D.; Pierce, S. R.; Brandt, M.; Byrd, A.; Bekele, B. N.; Pratz, K.; Luthra, R.; Levis, M.; Andreeff, M.; Kantarjian, H. M. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J. Clin. Oncol. 2010, 28, 1856-1862.
56. Al-Kali, A.; Cortes, J.; Faderl, S.; Jones, D.; Abril, C.; Pierce, S.; Brandt, M.; Kantarjian, H.; Ravandi, F. Patterns of molecular response to and relapse after combination of Sorafenib, Idarubicin, and Cytarabine in patients With FLT3 mutant Acute Myeloid Leukemia. Clin. Lymphoma Myeloma Leuk. 2011, 11, 361-366.
57. Safaian, N. N.; Czibere, A.; Bruns, I.; Fenk, R.; Reinecke, P.; Dienst, A.; Haas, R.; Kobbe, G. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk. Res. 2009, 33, 348-350.
58. Metzelder, S.; Wang, Y.; Wollmer, E.; Wanzel, M.; Teichler, S.; Chaturvedi, A.; Eilers, M.; Enghofer, E.; Neubauer, A.; Burchert, A. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113, 6567-6571.
59. Sharma, M.; Ravandi, F.; Bayraktar, U. D.; Chiattone, A.; Bashir, Q.; Giralt, S.; Chen, J.; Qazilbash, M.; Kebriaei, P.; Konopleva, M.; Andreeff, M.; Cortes, J.; McCue, D.; Kantarjian, H.; Champlin, R. E.; de Lima, M. Treatment of FLT3-ITD-positive Acute Myeloid Leukemia relapsing after allogeneic stem cell transplantation with Sorafenib. Biol. Blood Marrow Transplant. 2011.
60. Schroeder, T.; Zohren, F.; Saure, C.; Bruns, I.; Czibere, A.; Safaian, N. N.; Fenk, R.; Haas, R.; Kobbe, G. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy. Acta Haematol. 2010, 124, 153-159.
61. Stone, R.; Fischer, T.; Paquette, R.; et al. Phase IB Study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood 108 (11) 2006, 108.
62. Fischer, T.; Stone, R. M.; Deangelo, D. J.; Galinsky, I.; Estey, E.; Lanza, C.; Fox, E.; Ehninger, G.; Feldman, E. J.; Schiller, G. J.; Klimek, V. M.; Nimer, S. D.; Gilliland, D. G.; Dutreix, C.; Huntsman-Labed, A.; Virkus, J.; Giles, F. J. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J. Clin. Oncol. 2010, 28, 4339-4345.
63. Smith, B. D.; Levis, M.; Beran, M.; Giles, F.; Kantarjian, H.; Berg, K.; Murphy, K. M.; Dauses, T.; Allebach, J.; Small, D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103, 3669-3676.
64. Knapper, S.; Burnett, A. K.; Littlewood, T.; Kell, W. J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M. J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006, 108, 3262-3270.
65. Levis, M.; Ravandi, F.; Wang, E. S.; Baer, M. R.; Perl, A.; Coutre, S.; Erba, H.; Stuart, R. K.; Baccarani, M.; Cripe, L. D.; Tallman, M. S.; Meloni, G.; Godley, L. A.; Langston, A. A.; Amadori, S.; Lewis, I. D.; Nagler, A.; Stone, R.; Yee, K.; Advani, A.; Douer, D.; Wiktor-Jedrzejczak, W.; Juliusson, G.; Litzow, M. R.; Petersdorf, S.; Sanz, M.; Kantarjian, H. M.; Sato, T.; Tremmel, L.; Bensen-Kennedy, D. M.; Small, D.; Smith, B. D. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011, 117, 3294-3301.
66. Brugarolas, J. B.; Vazquez, F.; Reddy, A.; Sellers, W. R.; Kaelin, W. G.TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003, 4, 147-158.
67. Butzal, M.; Loges, S.; Schweizer, M.; Fischer, U.; Gehling, U. M.; Hossfeld, D. K.; Fiedler, W. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp. Cell Res. 2004, 300, 65-71.
68. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C. J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K. W.; Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8, 128-135.
69. Humar, R.; Kiefer, F. N.; Berns, H.; Resink, T. J.; Battegay, E. J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro viarapamycin (mTOR)-dependent signaling. FASEB J. 2002, 16, 771-780.
70. Bohm, A.; Aichberger, K. J.; Mayerhofer, M.; Herrmann, H.; Florian, S.; Krauth, M. T.; Derdak, S.; Samorapoompichit, P.; Sonneck, K.; Vales, A.; Gleixner, K. V.; Pickl, W. F.; Sperr, W. R.; Valent, P. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur. J. Clin. Invest. 2009, 39, 395-405.
71. Yee, K. W.; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandi, F.; Ferrajoli, A.; Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, F. J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2006, 12, 5165-5173.
72. Decker, T.; Sandherr, M.; Goetze, K.; Oelsner, M.; Ringshausen, I.; Peschel, C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann. Hematol. 2009, 88, 221-227.
73. Zent, C. S.; LaPlant, B. R.; Johnston, P. B.; Call, T. G.; Habermann, T. M.; Micallef, I. N.; Witzig, T. E. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116, 2201-2207.
74. Perl, A. E.; Kasner, M. T.; Tsai, D. E.; Vogl, D. T.; Loren, A. W.; Schuster, S. J.; Porter, D. L.; Stadtmauer, E. A.; Goldstein, S. C.; Frey, N. V.; Nasta, S. D.; Hexner, E. O.; Dierov, J. K.; Swider, C. R.; Bagg, A.; Gewirtz, A. M.; Carroll, M.; Luger, S. M. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin. Cancer Res. 2009, 15, 6732-6739.
75. Bartlett, J. B.; Tozer, A.; Stirling, D.; Zeldis, J. B. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br. J. Cancer 2005, 93, 613-619.
76. Lenz, W.; Knapp, K. Thalidomide embryopathy. Arch Environ. Health 1962, 5, 100-105.
77. McBride, W. G. The Teratogenic Action of Drugs. Med. J. Aust. 1963, 2, 689-692.
78. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 4082-4085.
79. Raza, A.; Meyer, P.; Dutt, D.; Zorat, F.; Lisak, L.; Nascimben, F.; du Randt, M.; Kaspar, C.; Goldberg, C.; Loew, J.; Dar, S.; Gezer, S.; Venugopal, P.; Zeldis, J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98, 958-965.
80. Musto, P.; Falcone, A.; Sanpaolo, G.; Bisceglia, M.; Matera, R.; Carella, A. M. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica 2002, 87, 884-886.
81. Strupp, C.; Germing, U.; Aivado, M.; Misgeld, E.; Haas, R.; Gattermann, N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002, 16, 1-6.
82. Strupp, C.; Hildebrandt, B.; Germing, U.; Haas, R.; Gattermann, N. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 2003, 17, 1200-1202.
83. Moreno-Aspitia, A.; Colon-Otero, G.; Hoering, A.; Tefferi, A.; Niedringhaus, R. D.; Vukov, A.; Li, C. Y.; Menke, D. M.; Geyer, S. M.; Alberts, S. R. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer 2006, 107, 767-772.
84. Steins, M. B.; Padro, T.; Bieker, R.; Ruiz, S.; Kropff, M.; Kienast, J.; Kessler, T.; Buechner, T.; Berdel, W. E.; Mesters, R. M. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002, 99, 834-839.
85. Thomas, D. A.; Estey, E.; Giles, F. J.; Faderl, S.; Cortes, J.; Keating, M.; O'Brien, S.; Albitar, M.; Kantarjian, H. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br. J. Haematol. 2003, 123, 436-441.
86. Cortes, J.; Kantarjian, H.; Albitar, M.; Thomas, D.; Faderl, S.; Koller, C.; Garcia-Manero, G.; Giles, F.; Andreeff, M.; O'Brien, S.; Keating, M.; Estey, E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2003, 97, 1234-1241.
87. Barr, P.; Fu, P.; Lazarus, H.; Kane, D.; Meyerson, H.; Hartman, P.; Reyes, R.; Creger, R.; Stear, K.; Laughlin, M.; Tse, W.; Cooper, B. Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leuk. Lymphoma 2007, 48, 1940-1949.
88. Anderson, K. C. Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin. Hematol. 2005, 42, S3-8.
89. List, A.; Kurtin, S.; Roe, D. J.; Buresh, A.; Mahadevan, D.; Fuchs, D.; Rimsza, L.; Heaton, R.; Knight, R.; Zeldis, J. B. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 2005, 352, 549-557.
90. List, A.; Dewald, G.; Bennett, J.; Giagounidis, A.; Raza, A.; Feldman, E.; Powell, B.; Greenberg, P.; Thomas, D.; Stone, R.; Reeder, C.; Wride, K.; Patin, J.; Schmidt, M.; Zeldis, J.; Knight, R. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 2006, 355, 1456-1465.
91. Kurtin, S. E.; List, A. F. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. Clin. Lymphoma Myeloma 2009, 9, E10-13.
92. Sekeres, M. A.; List, A. F.; Cuthbertson, D.; Paquette, R.; Ganetzky, R.; Latham, D.; Paulic, K.; Afable, M.; Saba, H. I.; Loughran, T. P., Jr.; Maciejewski, J. P. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J. Clin. Oncol. 2010, 28, 2253-2258.
93. Fehniger, T. A.; Uy, G. L.; Trinkaus, K.; Nelson, A. D.; Demland, J.; Abboud, C. N.; Cashen, A. F.; Stockerl-Goldstein, K. E.; Westervelt, P.; Dipersio, J. F.; Vij, R. A phase II study of high dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2010, 117, 1828-1833.
94. Ades, L.; Boehrer, S.; Prebet, T.; Beyne-Rauzy, O.; Legros, L.; Ravoet, C.; Dreyfus, F.; Stamatoullas, A.; Chaury, M. P.; Delaunay, J.; Laurent, G.; Vey, N.; Burcheri, S.; Mbida, R. M.; Hoarau, N.; Gardin, C.; Fenaux, P. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009, 113, 3947-3952.
95. Chanan-Khan, A.; Miller, K. C.; Musial, L.; Lawrence, D.; Padmanabhan, S.; Takeshita, K.; Porter, C. W.; Goodrich, D. W.; Bernstein, Z. P.; Wallace, P.; Spaner, D.; Mohr, A.; Byrne, C.; Hernandez-Ilizaliturri, F.; Chrystal, C.; Starostik, P.; Czuczman, M. S. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J. Clin. Oncol. 2006, 24, 5343-5349.
96. Andritsos, L. A.; Johnson, A. J.; Lozanski, G.; Blum, W.; Kefauver, C.; Awan, F.; Smith, L. L.; Lapalombella, R.; May, S. E.; Raymond, C. A.; Wang, D. S.; Knight, R. D.; Ruppert, A. S.; Lehman, A.; Jarjoura, D.; Chen, C. S.; Byrd, J. C. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2008, 26, 2519-2525.
97. Chanan-Khan, A.; Miller, K. C.; Lawrence, D.; Padmanabhan, S.; Miller, A.; Hernandez-Illatazurri, F.; Czuczman, M. S.; Wallace, P. K.; Zeldis, J. B.; Lee, K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011, 117, 2127-2135.
98. Ferrajoli, A.; Lee, B. N.; Schlette, E. J.; O'Brien, S. M.; Gao, H.; Wen, S.; Wierda, W. G.; Estrov, Z.; Faderl, S.; Cohen, E. N.; Li, C.; Reuben, J. M.; Keating, M. J. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111, 5291-5297.
99. Sher, T.; Miller, K. C.; Lawrence, D.; Whitworth, A.; Hernandez-Ilizaliturri, F.; Czuczman, M. S.; Miller, A.; Lawrence, W.; Bilgrami, S. A.; Sood, R.; Wood, M. T.; Block, A. W.; Lee, K.; Chanan-Khan, A. A. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk. Lymphoma 2010, 51, 85-88.
100. Brown, J. R.; Abramson, J.; Hochberg, E.; Mikler, E.; Dalton, V.; Werner, L.; Reynolds, H.; Thompson, C.; McDonough, S. M.; Kuang, Y.; Ritz, J.; Neuberg, D.; Freedman, A. S. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010, 24, 1972-1975.
101. Sole, F.; Espinet, B.; Sanz, G. F.; Cervera, J.; Calasanz, M. J.; Luno, E.; Prieto, F.; Granada, I.; Hernandez, J. M.; Cigudosa, J. C.; Diez, J. L.; Bureo, E.; Marques, M. L.; Arranz, E.; Rios, R.; Martinez Climent, J. A.; Vallespi, T.; Florensa, L.; Woessner, S. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br. J. Haematol. 2000, 108, 346-356.
102. Di Costanzo, F.; Mazzoni, F.; Micol Mela, M.; Antonuzzo, L.; Checcacci, D.; Saggese, M. Bevacizumab in non-small cell lung cancer. Drugs 2008, 68, 737-746.
103. Johnson, D. H.; Fehrenbacher, L.; Novotny, W. F.; Herbst, R. S.; Nemunaitis, J. J.; Jablons, D. M.; Langer, C. J.; DeVore, R. F., 3rd; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
104. Kabbinavar, F. F.; Hambleton, J.; Mass, R. D.; Hurwitz, H. I.; Bergsland, E.; Sarkar, S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 2005, 23, 3706-3712.
105. Kuzu, I.; Beksac, M.; Arat, M.; Celebi, H.; Elhan, A. H.; Erekul, S. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk. Lymphoma 2004, 45, 1185-1190.
106. Herbst, R. S.; Hong, D.; Chap, L.; Kurzrock, R.; Jackson, E.; Silverman, J. M.; Rasmussen, E.; Sun, Y. N.; Zhong, D.; Hwang, Y. C.; Evelhoch, J. L.; Oliner, J. D.; Le, N.; Rosen, L. S. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J. Clin. Oncol. 2009, 27, 3557-3565.
107. Mita, A. C.; Takimoto, C. H.; Mita, M.; Tolcher, A.; Sankhala, K.; Sarantopoulos, J.; Valdivieso, M.; Wood, L.; Rasmussen, E.; Sun, Y. N.; Zhong, Z. D.; Bass, M. B.; Le, N.; LoRusso, P. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin. Cancer Res. 2010, 16, 3044-3056.
108. Veikkola, T.; Alitalo, K. Dual role of Ang2 in postnatal angiogenesis and lymphangiogenesis. Dev. Cell 2002, 3, 302-304.
109. Koh, Y. J.; Kim, H. Z.; Hwang, S. I.; Lee, J. E.; Oh, N.; Jung, K.; Kim, M.; Kim, K. E.; Kim, H.; Lim, N. K.; Jeon, C. J.; Lee, G. M.; Jeon, B. H.; Nam, D. H.; Sung, H. K.; Nagy, A.; Yoo, O. J.; Koh, G. Y. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010, 18, 171-184.
110. Borset, M.; Seidel, C.; Hjorth-Hansen, H.; Waage, A.; Sundan, A. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk. Lymphoma 1999, 32, 249-256.
111. Gohda, E.; Nakamura, S.; Yamamoto, I.; Minowada, J. Hepatocyte growth factor--pleiotropic cytokine produced by human leukemia cells. Leuk. Lymphoma 1995, 19, 197-205.
112. Naran, S.; Zhang, X.; Hughes, S. J. Inhibition of HGF/MET as therapy for malignancy. Expert Opin. Ther. Targets 2009, 13, 569-581.
113. Laterra, J.; Nam, M.; Rosen, E.; Rao, J. S.; Lamszus, K.; Goldberg, I. D.; Johnston, P. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab. Invest. 1997, 76, 565-577.
114. Rosen, E. M.; Zitnik, R. J.; Elias, J. A.; Bhargava, M. M.; Wines, J.; Goldberg, I. D. The interaction of HGF-SF with other cytokines in tumor invasion and angiogenesis. EXS 1993, 65, 301-310.
115. Van Belle, E.; Witzenbichler, B.; Chen, D.; Silver, M.; Chang, L.; Schwall, R.; Isner, J. M. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor viainduction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998, 97, 381-390.
116. Heideman, D. A.; Overmeer, R. M.; van Beusechem, V. W.; Lamers, W. H.; Hakvoort, T. B.; Snijders, P. J.; Craanen, M. E.; Offerhaus, G. J.; Meijer, C. J.; Gerritsen, W. R. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther. 2005, 12, 954-962.
117. Puri, N.; Khramtsov, A.; Ahmed, S.; Nallasura, V.; Hetzel, J. T.; Jagadeeswaran, R.; Karczmar, G.; Salgia, R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007, 67, 3529-3534.
118. Eder, J. P.; Shapiro, G. I.; Appleman, L. J.; Zhu, A. X.; Miles, D.; Keer, H.; Cancilla, B.; Chu, F.; Hitchcock-Bryan, S.; Sherman, L.; McCallum, S.; Heath, E. I.; Boerner, S. A.; LoRusso, P. M. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 2010, 16, 3507-3516.
119. Yap, T. A.; Olmos, D.; Brunetto, A. T.; Tunariu, N.; Barriuso, J.; Riisnaes, R.; Pope, L.; Clark, J.; Futreal, A.; Germuska, M.; Collins, D.; deSouza, N. M.; Leach, M. O.; Savage, R. E.; Waghorne, C.; Chai, F.; Garmey, E.; Schwartz, B.; Kaye, S. B.; de Bono, J. S. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol. 2011, 29, 1271-1279.